![]() |
|
|
|||||||
|
|
LinkBack | Thread Tools | Display Modes |
|
|||
|
Pfizer Inc. announced today that the U.S. Food and Drug Administration has approved INLYTA® , a kinase inhibitor, for the treatment of patients with advanced renal cell carcinoma after failure of one prior systemic therapy.
|
| Thread Tools | |
| Display Modes | |
|
|